• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·RDNT
Held by 2 Gurus
Share

RadNet, Inc. Stocks

$ 65.6Last Updated 10.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

$ 5.16B

$ 65.6
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Manager
Fund
Portfolio Weight (%)
Change
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Sign up, to see portfolios that hold this stock
Sign up, to see portfolios that hold this stock

Latest news

17.12.2025 15:10

Morning in New York: foreign policy news is the market's focus

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of RDNT is 87.1 and suggests 32% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.07.2026 19:01

A Triumph for City Governments? How China’s Scaling Model Will Change the Global AI Market

11.07.2026 16:01

Highlights from Small-Caps: Royce Fund Forecast, Trump's Sons' Investments, the Chewy Case Study

11.07.2026 15:32

SK Hynix's Record-Breaking IPO: What's Behind the Hype Surrounding Memory Chip Manufacturers

11.07.2026 13:01

Where Holann Is Investing, AI to Focus on Pharmaceuticals, and SK Hynix's Record-Breaking Offering

11.07.2026 12:20

Freedom Holding Raised $300 Million for International Expansion

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026